---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-125309"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-12-31T23:59:59+00:00"
generated_at: "2026-05-16T11:53:55.599997+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D

## Summary
- Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).
- As of Nov 26, 2025: doublet in G12C-naive patients achieved ORR 40% (12/30), mPFS 11.1 months.
- Previously G12C-treated patients in doublet: ORR 9.5% (2/21), mPFS 3.7 months.
- Triplet combo: ORR 50% (2/4) in naive; 36% (4/11) tumor reduction in pretreated.
- VS-7375 showed 69% ORR (11/16) in KRAS G12D NSCLC; no DLTs observed across RAMP 203.

## SEC filing metadata
- accession: 0001104659-25-125309
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/0001104659-25-125309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/tm2534532d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-125309
- JSON: https://secwatch.observer/filing/0001104659-25-125309.json
- Plain text: https://secwatch.observer/filing/0001104659-25-125309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.